Ko Ryoung-Eun, Min Kyung Hoon, Hong Sang-Bum, Baek Ae-Rin, Lee Hyun-Kyung, Cho Woo Hyun, Kim Changhwan, Chang Youjin, Lee Sung-Soon, Oh Jee Youn, Lee Heung Bum, Bae Soohyun, Moon Jae Young, Yoo Kwang Ha, Jeon Kyeongman
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Tuberc Respir Dis (Seoul). 2021 Oct;84(4):317-325. doi: 10.4046/trd.2021.0018. Epub 2021 Jun 4.
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are significant public health issues in the world, but the epidemiological data pertaining to HAP/VAP is limited in Korea. The objective of this study was to investigate the characteristics, management, and clinical outcomes of HAP/VAP in Korea.
This study is a multicenter retrospective cohort study. In total, 206,372 adult patients, who were hospitalized at one of the 13 participating tertiary hospitals in Korea, were screened for eligibility during the six-month study period. Among them, we included patients who were diagnosed with HAP/VAP based on the Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) definition for HAP/VAP.
Using the IDSA/ATS diagnostic criteria, 526 patients were identified as HAP/VAP patients. Among them, 27.9% were diagnosed at the intensive care unit (ICU). The cohort of patients had a median age of 71.0 (range from 62.0 to 79.0) years. Most of the patients had a high risk of aspiration (63.3%). The pathogen involved was identified in 211 patients (40.1%). Furthermore, multidrug resistant (MDR) pathogens were isolated in 138 patients; the most common MDR pathogen was Acinetobacter baumannii. During hospitalization, 107 patients with HAP (28.2%) had to be admitted to the ICU for additional care. The hospital mortality rate was 28.1% in the cohort of this study. Among the 378 patients who survived, 54.2% were discharged and sent back home, while 45.8% were transferred to other hospitals or facilities.
This study found that the prevalence of HAP/VAP in adult hospitalized patients in Korea was 2.54/1,000 patients. In tertiary hospitals in Korea, patients with HAP/VAP were elderly and had a risk of aspiration, so they were often referred to step-down centers.
医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)是全球重大的公共卫生问题,但韩国有关HAP/VAP的流行病学数据有限。本研究的目的是调查韩国HAP/VAP的特征、管理及临床结局。
本研究是一项多中心回顾性队列研究。在为期6个月的研究期间,对在韩国13家参与研究的三级医院之一住院的206,372例成年患者进行了资格筛查。其中,我们纳入了根据美国感染病学会(IDSA)/美国胸科学会(ATS)对HAP/VAP的定义被诊断为HAP/VAP的患者。
采用IDSA/ATS诊断标准,526例患者被确定为HAP/VAP患者。其中,27.9%在重症监护病房(ICU)被诊断。该队列患者的中位年龄为71.0岁(范围62.0至79.0岁)。大多数患者有误吸高风险(63.3%)。211例患者(40.1%)确定了所涉及的病原体。此外,138例患者分离出多重耐药(MDR)病原体;最常见的MDR病原体是鲍曼不动杆菌。住院期间,107例HAP患者(28.2%)不得不入住ICU接受进一步治疗。本研究队列的医院死亡率为28.1%。在378例存活患者中,54.2%出院回家,而45.8%被转至其他医院或机构。
本研究发现,韩国成年住院患者中HAP/VAP患病率为2.54/1000例患者。在韩国的三级医院中,HAP/VAP患者年龄较大且有误吸风险,因此常被转诊至降级护理中心。